FDA Approved: GAZYVA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for GAZYVA (obinutuzumab) from Genentech to expand its approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)

Snippet

SUPPL AP for GAZYVA (OBINUTUZUMAB)